Nuvaira CEO Dennis Wahr, MD, sees similarities between interventional pulmonology today and interventional cardiology in its early days. He hopes Nuvaira, which is developing a tool to ablate lung tissue, will be able to further the field through upcoming clinical trials and fund-raising.